Wedbush Equities Analysts Lift Earnings Estimates for BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at Wedbush boosted their Q2 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a research note issued on Monday, May 5th. Wedbush analyst L. Chico now anticipates that the biotechnology company will earn $0.00 per share for the quarter, up from their previous forecast of ($0.03). Wedbush currently has a “Outperform” rating and a $15.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ FY2025 earnings at $0.11 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.14 EPS, Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at $0.68 EPS.

Several other research firms have also recently issued reports on BCRX. Barclays upped their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price objective for the company. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Needham & Company LLC lifted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $9.98 on Thursday. The firm’s 50 day moving average price is $7.87 and its 200-day moving average price is $7.89. BioCryst Pharmaceuticals has a 52-week low of $5.23 and a 52-week high of $11.11. The company has a market cap of $2.09 billion, a PE ratio of -16.36 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. During the same period in the previous year, the company posted $0.28 earnings per share. BioCryst Pharmaceuticals’s revenue was up 40.8% compared to the same quarter last year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allianz Asset Management GmbH raised its stake in shares of BioCryst Pharmaceuticals by 9.6% in the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock worth $103,000 after buying an additional 1,200 shares during the period. Xponance Inc. raised its stake in BioCryst Pharmaceuticals by 9.1% during the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 1,242 shares during the period. Sei Investments Co. raised its stake in BioCryst Pharmaceuticals by 2.8% during the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock worth $430,000 after acquiring an additional 1,537 shares during the period. SG Americas Securities LLC lifted its holdings in BioCryst Pharmaceuticals by 5.2% during the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 2,146 shares in the last quarter. Finally, Mariner LLC boosted its position in shares of BioCryst Pharmaceuticals by 32.1% in the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,224 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.